1. Academic Validation
  2. Ex vivo mass spectrometry-based biodistribution analysis of an antibody-Resiquimod conjugate bearing a protease-cleavable and acid-labile linker

Ex vivo mass spectrometry-based biodistribution analysis of an antibody-Resiquimod conjugate bearing a protease-cleavable and acid-labile linker

  • Front Pharmacol. 2023 Dec 6:14:1320524. doi: 10.3389/fphar.2023.1320524.
Lydia Bisbal Lopez 1 Domenico Ravazza 2 Matilde Bocci 2 Aureliano Zana 2 Lucrezia Principi 2 Sheila Dakhel Plaza 2 Andrea Galbiati 2 Ettore Gilardoni 2 Jörg Scheuermann 3 Dario Neri 2 3 4 Luca Pignataro 1 Cesare Gennari 1 Samuele Cazzamalli 2 Alberto Dal Corso 1
Affiliations

Affiliations

  • 1 Chemistry Department, Università degli Studi di Milano, Milano, Italy.
  • 2 R&D Department, Philochem AG, Otelfingen, Switzerland.
  • 3 Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zürich, Switzerland.
  • 4 Philogen S.p.A, Siena, Italy.
Abstract

Immune-stimulating antibody conjugates (ISACs) equipped with imidazoquinoline (IMD) payloads can stimulate endogenous immune cells to kill Cancer cells, ultimately inducing long-lasting Anticancer effects. A novel ISAC was designed, featuring the IMD Resiquimod (R848), a tumor-targeting antibody specific for Carbonic Anhydrase IX (CAIX) and the protease-cleavable Val-Cit-PABC linker. In vitro stability analysis showed not only R848 release in the presence of the protease Cathepsin B but also under acidic conditions. The ex vivo mass spectrometry-based biodistribution data confirmed the low stability of the linker-drug connection while highlighting the selective accumulation of the IgG in tumors and its long circulatory half-life.

Keywords

Resiquimod; immune stimulating antibody conjugates; prodrugs; quantitative biodistribution; toll-like receptors.

Figures
Products